| abstract |
Various novel recombinant chimeric human rhinoviruses are disclosed, including viruses comprising human rhinovirus 14 into which chimeric regions derived from influenza HA, poliovirus and HIV-1 have been incorporated. Chimeric human rhinoviruses are particularly advantageous as they are only mildly pathogenic, have numerous potential serotypes and can elicit significant mucosal and serum immunological response. Design considerations, methods, and examples are described. The chimeric rhinoviruses can be used as vaccines and for a variety of other immunotechnological applications including passive immunization, immunodiagnostic testing and antigenicity and immunogenicity studies. |